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Human plasma lipoprotein(a) (Lp(a)) is a macromolecular complex that contams a protem homologous to plasminogen. the precursor of plasmin. 
We confirmed recent reports that Lp(a) is not activated by streptokinase or tissue plasminogen activator (t-PA) to yreld plasmm-like activtty. In 
testing the hypothesis that Lp(a) can competittvely inhabit plasma clot lys~s medtated by plasmm, the present study shows that Lp(a) stgmficantly 
enhanced plasma clot lysis mediated by streptokmase or t-PA The enhancement, however, was not observed in a plasmm-medtated clot lysts usmg 
a purtfied fibrinogen system. The addttion of x-,-anttplasmm (%-plasmin inhibitor) to thts system inhtbited tibrinolysts: however, no inhibition 
was observed in the presence of Lp(a). One potential explanation for the Lp(a)-enhanced plasma clot lysis is that Lp(a) neutrahzes the activtty 
of a,-antiplasmm present m plasma, thereby restormg the acttvtty of plasmm to lyse the clot. 
Ltpoprotein(a); Plasmmogen; Fibrmolysis; %-Plasmm mhtbttor; a,-Antiplasmin 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Lipoprotein(a) (Lp(a)) was first identified by Berg in 
1963 [I]. The particle contains one copy of apolipopro- 
tein(a) which is disulfide-linked to apolipoprotein B. 
The molecular mass of Lp(a) is approximately 3.8 x lo6 
121. Plasma Lp(a) levels are positively correlated with 
atherosclerosis (see [3] for review) and is an indepen- 
dent risk factor for myocardial infarction [4-81. The 
amino acid sequence of apolipoprotein(a) has a high 
degree of homology with plasminogen. Lp(a) contains 
37 copies of kringle 4-like, 1 copy of kringle 5-like, and 
1 copy of catalytic-like domain of plasminogen [9,10]. 
Plasminogen is a zymogen that has to be converted into 
plasmin by plasminogen activators prior to fibrinolysis 
(see [l l] for review). However, Lp(a) cannot be ac- 
tivated by tissue plasminogen activator (t-PA), 
urokinase, or streptokinase to obtain plasmin-like ac- 
tivity [9, lo]. Since a proteolytically active form of 
Lp(a) is not produced, it has been speculated that Lp(a) 
may act as a competitive inhibitor for plasminogen ac- 
tivation [9, lo]. Whether or not Lp(a) can protect fibrin 
from plasmin degradation has not been established. 
Harpel et al. [12] reported that Lp(a) binds to fibrin 
and fibrinogen. They suggested that the binding might 
inhibit plasmin-mediated thrombus (fibrin) degrada- 
tion. This hypothesis, however, has never been tested. 
In the present study we show that Lp(a) did not retard 
plasma clot lysis; rather, Lp(a) enhanced lysis in vitro. 
The possible mechanism by which Lp(a) enhances 
plasma clot lysis is discussed. 
2.1. Preparaflon of Lp(a) 
Human Lp(a) was a generous gift from Dr Thomas Parker 
(Rogosin Institute, New York, NY). The plasma sample was obtained 
from a donor with an elevated Lp(a). Lp(a) was isolated according to 
the procedure described in [12]. Purified Lp(a) showed a single band, 
distinct from LDL, by non-denaturing polyacrylamide gradient gel 
(2%16%) electrophoresis. 
2.2. Preparation of a plasma clot 
Plasma collected in a final EDTA concentratton of 0.1% was 
filtered and aliquoted into 1 ml microcentrifuge tubes and stored at 
--80°C. For the preparatton of clots, 100~1 of plasma (1 :5) in a 
phosphate-buffered saline (PBS) containing 0.01 M phosphate, 
0.12 M NaCl and 0.1% bovine serum albumin (BSA), pH 7.4, were 
added to microtiter wells. To these wells SO pl of bovine thrombin 
(Sigma) containing 0.25 NIH units were added according to the 
method of [ 131. The final volume in each well was 150 pl. Clot forma- 
tion occurred after 45 min at 24°C. Clot turbidity was recorded at 
380 nm with an automated EIA plate reader (EL309, Bio-tek in- 
struments, VA). 
2.3. Cl0 t lysis 
Fifty ,4cl of streptokinase (2.5 mg/ml; Sigma) or recombinant t-PA 
(5 W/ml; Genentech) were added to 20 pl of Lp(a) at concentrattons 
from 0 to 4 mg/ml. The reaction mixture was then carefully layered 
on top of the microtiter well containing the plasma clot. Clearance of 
clot turbidtty was recorded at 380 nm for 50-60 min. 
2.4. Plasmm assav 
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Plasmin activity was determined using the chromogenic substrate 
S-225 1 (H-D-Val-Leu-Lys-p-nitroanilide.2HCI (KabiVitrum, 
Stockholm, Sweden)). The activity ts based on the rate of pNA for- 
mation from the hydrolysis of S-225 1. Plasmin (10 U/ml) purchased 
from Sigma was appropriately diluted (in PBS containing 0.1% BSA) 
so that the rate of hydrolysis of S-2251 was linear during the first 
30 min. For a typical assay, 50 ~1 of S-2251 (1.75 mM) was added to 
SO pl of plasmin (diluted to 1 : 320) preincubated with or without 
Lp(a). The increase in absorbance was monitored at 405 nm and data 
recorded over a 35 mm period. To activate plasminogen (Sigma), 
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50 ~1 of plasminogen (0.5 U/ml in 0.1% BSA) were preincubated 
with 50 pl of streptokinase (2 m&ml, Sigma) for 30 min at 24°C. Flf- 
ty yl of the reaction mixture were then added to 50~1 of S-2251 
(1.75 mM) and the hydrolysis of S-2251 was momtored over a 15 mm 
period 
2.5. Deterrnmatron of the effect ofl.p(al on cYz-antrp~asmm acttvify 
on frbrmolysts Induced b_v p(asmm 
Fibrinogen (Sigma) was dissolved m PBS containing 0.1% BSA 
and centrifuged at 3000 rpm to remove any insoluble materials. For 
the preparation of the clot, 30 pl of 1 mg/ml Coomassie blue R-250 
(Eho-Rad) were added to 200~1 of 5 mg/ml fibrinogen in 
polypropylene test tubes (12 x 75 mm). After 5 min incubation at 
24”C, 100~1 of bovine thrombin (Sigma) containing 0.25 NIH units 
were added to initiate the fibrin clot. Clots were formed after 30 min 
incubation at 24°C. 
Fibrmolysls was initiated by plasmin add&Ion and the rate of 
fibrinolysis was determined by the chromogenic substances released 
from the clots. Assaying for clearance of turbidity could not be used 
due to the lack of turbidity of the fibrm clot. The fibrinolysis was 
allowed to proceed for 60 min at 24”C, at which time about 50% of 
maximal lysis was achieved. At this time 100~1 of the supernatant 
fraction were removed from each clot and placed into the wells of a 
microtlter plate. Absorbance was recorded at 540 nm. To study the 
effect of Lpfa) on the activity of cz-antiptasmin, 100~1 of Lp(a) 
(8 mg/ml) was preincubated wzth 100 aI nz-antlplasmin (American 
Diagnostica, NY) (90 p&ml) for 30 min at 24°C before ad&ion of 
100 ~1 plasmm (3.5 U/ml). Final volume of the reaction mixture was 
adjusted to I .I6 ml with 0.1% BSA in PBS. 
3. RESULTS 
3. I. Effecr of Lp(a) on pias~~~ activity 
Effect of Lp(a) on the plasmin activity was studied. 
The enzyme activity was based on the hydrolysis of a 
chromogenic substrate S-225 1. Fig. 1 shows that Lp(a) 
at a final concentration of 0.33 mg/ml did not affect 
the activity of plasmin ranging from 0.016 to 0.5 U/ml. 
The activity remained the same when Lp(a) concentra- 
tion was increased to 4 mglml (data not shown). In the 
absence of plasmin, no detectable hydrolysis of S-2251 
was seen in the reaction mixture with and without 
Lp(a). Thus, the data indicate that even though Lp(a) 
is homologous with the catalytic domain of plasmin, it 
neither enhanced nor competitively inhibited plasmin 
activity. 
Since Lp(a) is structurally similar to plasminogen, we 
tested whether or not Lp(a) could be activated by a 
plasminogen activator, streptokinase. As shown in 
Fig. 2, plasminogen (0.5 mgfml) was maximally ac- 
tivated at streptokinase concentrations between 0.25 
and 1.25 mg/ml. Streptokinase at a concentration of 
1.25 mg/ml failed to activate Lp(a) (2 mg/ml). Similar 
results were seen when Lp(a) concentrations between 
0.1 and 4 mg/ml were tested (data not shown). The fin- 
ding suggests that Lpfa) is not readily activated by 
streptokinase. 
3.2. Effect of Lp(a) on plasma clot @is 
Under physiological conditions, the specificity of 
plasmin is determined primarily by its lysine-binding 
sites (substrate-binding) rather than by its protease- 
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Fig. 1. Effect of Lp(a) on the catalytic activtty of plasmin. Plasmin 
activity was determined using S-2251 (D-Va-Leu-Lys-pNA) as 
substrate. The reactton mixture contained 5041 of plasmm 
(0.016-0.5 U/ml), SO ~1 of substrate, and 50~1 of Lp(a) (1 mg/ml) 
or buffer. The hydrolysis of S-2251 was monitored at 405 nm. Each 
point represents the mean of duplicate determinations. 
catalytic site [14,15j. The lack of inhibition of Lp(a) on 
the hydrolysis of substrate S-2251 (as shown above) in- 
dicates that Lp(a) did not compete with the catalytic 
domain of plasmin. Thekysine-binding domain respon- 
sible for the binding of the fibrin substrate might in- 
terfere with Lp(a) due to the sequence homology [9,lOj. 
For this reason the effect of Lp(a) on clot Iysis was 
studied. Plasma clots were first allowed to form in 
microtiter plates; streptokinase in the presence of 
various amounts of Lp(a) (0.125-4 mg/mg) was then 
added to mediate clot lysis. Clearance of clot turbidity 
was recorded at 380 nm. Fig. 3A shows that the 
streptokinase-mediated clot lysis was enhanced by 
Lp(a) rather than inhibited. This enhancement was 
dependent on the amount of Lp(a). Regression analyses 
of the rate of clot Iysis showed a significant difference 
?‘lme (mm) 
Fig. 2. Effect of streptokinase (SK) on the activation of plasminogen 
and Lp(a). Plasminogen (0.5 mg/ml) or Lp(a) (2 mg/ml) was 
preincubated with streptukinase (0.25-l 25 mg/ml) in 100 pl for 
20 min at 24°C prior to the assay. 50 ~1 of substrate S-22.51 were then 
added to the assay well. The hydrolysis of S-2251 was monitored at 
405 nm. Each point represents the mean of duplicate determmations. 
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Fig. 3. Effect of Lp(a) on the clot lysis mediated by streptokinase (A) 
and t-PA (B). In the absence of streptokinase or t-PA, Lp(a) did not 
lyse the clot. Autolysis of the clot was not evident during the entire 
duration of the study. The assay contained 20~1 of Lp(a) from 
concentrations of O-4 mg/ml. Each point represents the mean of 
duplicate determinations. 
as compared to the control (P < 0.001). Lp(a) alone in 
the absence of streptokinase did not affect lysis (data 
not shown). A 20-fold molar excess of human low den- 
sity lipoproteins (LDL) or high density lipoproteins 
(HDL) had no effect on clot lysis (data not shown). 
In addition, the same enhancement by Lp(a) was 
observed using tissue plasminogen activator (t-PA) 
(Fig. 3B). At 4 mg/ml of Lp(a), the enhancement was 
significant (P < 0.001). Thus, the result provides 
Table 1 
Effect of Lp(a) on az-antiplasmin activity of fibrinogen clots 
Condition % Lysis * SD” 
Plasmin (control) 50 *2 
Buffer without plasmin 0 k1.5 
Lp(a) + buffer 0.1 + 4.2 
Plasmin + Lp(a) 48 &2 
Plasmin + cuz-antiplasmin 2.5 * 1.2 
Plasmin + cuz-antiplasmin + LDL 2.2 + 1.5 
Plasmin + az-antiplasmin + Lp(a) 54 * 1.5 
a Each value represents the mean f SD of 3 determinations 
Fibrinolysis was terminated at 60 min to obtain 50% of maximal 
lysis. Thrombin (100 ~1) was added to 230 pl of purified fibrinogen 
(3.85 mg/ml) containing Coomassie blue R-250 (0.025%) to medtate 
clot formation. A typical assay was performed using a 100 ~1 of 
plasmin (3.5 U/ml) and 100~1 of tested components in a final 
volume of 1.16 ml. The initial concentration of ruz-antiplasmin, 
LDL, and Lp(a) was 0.09, 10, and 8 mg/ml, respectively 
Fig. 4. A sample schematic drawing of a potential mechamsm of 
which Lp(a) enhances the streptokinase or t-PA mediated clot lysis in 
plasma. Step 1: in the absence of Lp(a), az-antiplasmin binds to the 
kringle 5 domain of plasmin and inhibits clot lysis. Step 2: in the 
presence of Lp(a), cul-antiplasmin competitively binds to Lp(a) and 
allows plasmin interaction with the clot. The size of each molecule 
drawn does not necessarily correspond to the actual molecular mass. 
evidence that there is no direct link between Lp(a) and 
inhibition of thrombolysis in vitro. 
3.3. Effect of Lp(a) on the inhibitory activity of 
al-antiplasmin for fibrinolysis 
Clot lysis, using purified fibrinogen as a clot 
substrate, was conducted. Fibrinolysis induced by the 
addition of plasmin was followed by the release of 
Coomassie blue R-250 labeled fibrinogen. Table I 
shows the plasmin-mediated clot lysis. In the absence of 
whole plasma, Lp(a) did not enhance fibrinolysis. The 
data suggest that Lp(a) might interact with a factor(s) 
that is normally present in plasma to regulate the 
plasmin activity (see section 4 for more details). In 
Table I, we show that plasmin inhibitor 
(trz-antiplasmin) inhibited the lysis activity of plasmin. 
In the presence of Lp(a), az-antiplasmin was not effec- 
tive in inhibiting fibrinolysis. Under the same condi- 
tions, LDL had no effect on az-antiplasmin. 
4. DISCUSSION 
Using a chromogenic substrate (S-2251), we show 
that Lp(a) did not affect the catalytic activity of 
plasmin. This result suggests that although there is 
structural homology between Lp(a) and the catalytic 
domain of plasmin, Lp(a) is not a competitive inhibitor 
for the catalytic-site of plasmin. Presumably, the con- 
formation of the ‘proteolytic domain’ of Lp(a) is fold- 
133 
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ed in such a way within the intact lipoprotein particles 
that it cannot bind the substrate. Whether or not Lp(a) 
is a zymogen that can be activated by other enzyme 
systems needs to be determined. 
Although Karadi et al. [16] have reported that Lp(a) 
prolongs the time required for fibrinolysis in an assay 
where fibrinolytic activity is stimulated with strep- 
tokinase, the present study was unable to show the 
same effect. Under their experimental conditions, the 
euglobulin fraction from plasma was first precipitated 
before the addition of thrombin to induce the clot. In- 
itially, the mechanism(s) by which Lp(a) enhanced 
plasma clot lysis in the present study was not clear. It 
is not because Lp(a) contains plasmin activity (Fig. 1) 
nor is it caused by the activation of Lp(a) by strep- 
tokinase (Fig. 2). It is known, however, that plasmin in 
the circulation does not effectively cause fibrinolysis of 
plasma clots. Plasmin is rapidly bound to circulating 
proteins, such as cuz-plasmin inhibitor (auz-antiplasmin) 
and az-macroglobulin which inhibit plasmin activity 
[ 171. It is believed that az-antiplasmin specifically binds 
to the kringle 5 domain of plasmin (lysine-binding sites) 
and thereby inactivates the plasmin recognition of 
fibrin clots [ 151. Since Lp(a) contains 91% sequence 
homology with plasmin kringle 5 [lo], we speculated 
that Lp(a) might also interact with az-antiplasmin to 
‘neutralize’ its activity. This potential mechanism is 
diagrammed in Fig. 4. The present study shows that 
Lp(a) is capable of reversing the inhibitory effects of 
auz-antiplasmin and, therefore, supports our specula- 
tion. The mode and physiologic role of the interaction 
between Lp(a) and az-antiplasmin are not known and 
deserve further study. 
The lack of direct inhibitory activity of Lp(a) for 
fibrinolysis may be contributed to its weak binding to 
fibrin [IO]. Although Kluft et al. [18] reported the 
absence of fibrin binding of Lp(a), a recent study [12] 
shows that plasmin mediates the binding of Lp(a) to 
immobilized fibrinogen and fibrin and indicates that 
Lp(a) possesses a site that interacts with fibrinogen or 
fibrin. They suggest that such interactions would im- 
pair plasminogen binding to fibrin and thereby might 
inhibit fibrinolysis [12], but the effect of Lp(a) on 
fibrinolysis in plasma was not studied. 
In summary, the present study shows that Lp(a) pro- 
motes the lysis of a plasma clot in vitro. As such, it 
seems unlikely that the postulated atherogenic role of 
Lp(a) can be explained by its direct inhibition of 
fibrinolysis. However, on the cellular level, Lp(a) 
displaces plasminogen from binding to the endothelial 
surface [19,20]. Therefore, the link between impaired 
cell surface fibrinolysis on the arterial wall and pro- 
gressive atherosclerosis as suggested [ 19,201, cannot be 
ruled out. 
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